SynBioBeta Speaker
Esthèle Goure
Bio Base Europe Pilot Plant
BD Manager
Esthèle Goure holds an MSc in Biotechnology from Polytech Marseille and a second MSc in Business Administration from Kedge Business School (France). She started her career in the Belgian biopharmaceutical industry in commercial roles and onboarded numerous investment projects linked to process development, scale-up and commercial activities associated with different research pipelines and modalities. In 2023, she broadened her focus to industrial biotechnology and bioeconomy topics when joining Bio Base Europe Pilot Plant in Ghent. First as Project Acquisition Coordinator, where Esthèle successfully set up EU project proposals and supported coordination of several EU-funded projects, and then switched to the Business Development group, where she now helps new customers implement their scale-up strategy at BBEPP. While supporting bilateral collaboration at BBEPP, she is also coordinating the newly launched SAN program to address the technical mentoring needs of start-ups as they begin their scale-up journey.
SynBioBeta 2026 Tickets are Live
Confirmed Speakers
Sessions Featuring
Esthèle
This Year
•
-
Biomanufacturing
Mind the Gap: Survival Guides for the Valleys of Death in Biomanufacturing
Industrial biotech faces repeated “valleys of death” between laboratory success and commercial manufacturing, driven by a combination of technological uncertainty, scale-dependent constraints, and (mis)alignment between engineering reality and investment expectations. Promising technologies often fail not because the science is wrong, but because scale-up trajectories are built on insufficient data, optimistic assumptions, and decision-making based on the 1st product specifications from the lab that do not translate to industrial conditions. This panel returns to fundamentals, drawing on real-world experience from piloting, process engineering, and early industrialization to examine where and why scale-up breaks down. Experts will discuss how important the scale-up journey is to align technology performance with investor expectations, support sound business cases, and turn the industrial biotech toolbox into a more robust, scalable, and profitable manufacturing platform.
•
-
Biomanufacturing
Mind the Gap: Survival Guides for the Valleys of Death in Biomanufacturing
Industrial biotech faces repeated “valleys of death” between laboratory success and commercial manufacturing, driven by a combination of technological uncertainty, scale-dependent constraints, and (mis)alignment between engineering reality and investment expectations. Promising technologies often fail not because the science is wrong, but because scale-up trajectories are built on insufficient data, optimistic assumptions, and decision-making based on the 1st product specifications from the lab that do not translate to industrial conditions. This panel returns to fundamentals, drawing on real-world experience from piloting, process engineering, and early industrialization to examine where and why scale-up breaks down. Experts will discuss how important the scale-up journey is to align technology performance with investor expectations, support sound business cases, and turn the industrial biotech toolbox into a more robust, scalable, and profitable manufacturing platform.
Session lineup still growing
Featuring
Speaker Coming Soon
•
-
Human Health
From Cells to Patients: Solving the Scale Mismatch in Virtual Biology
Drug discovery often measures biology at the cell level while interventions work at the tissue, organ, or whole-patient scale. This mismatch can make accurate cell-level predictions irrelevant in the clinic. This session dives into strategies to bridge that gap: multiscale modeling that nests single-cell dynamics within organ-level simulations, spatial transcriptomics that preserve context, and surrogate models that translate cell-level outputs into clinical biomarkers. Speakers will ask: how do we ensure virtual biology reflects not just what cells do in isolation, but how biology behaves in the real complexity of patients?
Featuring
Speaker Coming Soon
